ClinicalTrials.Veeva

Menu

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Alexion Pharmaceuticals logo

Alexion Pharmaceuticals

Status

Completed

Conditions

PNH
Paroxysmal Nocturnal Hemoglobinuria

Study type

Observational

Funder types

Industry

Identifiers

NCT01412047
M07-003

Details and patient eligibility

About

How does long term treatment with Soliris affect HAHA in PNH patients?

Full description

To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.

Enrollment

75 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • PNH patients who previously participated in study E05-001;
  • Patients who have an eculizumab naive serum sample for comparison;
  • Patients who currently used commerical Soliris;
  • Patients who are willing and able to gie written informed consent.

Exclusion criteria

  • There are no exclusion criteria for this study.

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems